

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Telix Pharmaceuticals Limited
<b>ABN</b>	85 616 620 369

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Dr Christian Behrenbruch
<b>Date of last notice</b>	12 March 2025

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct interest
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/A
<b>Date of change</b>	13 June 2025
<b>No. of securities held prior to change</b>	<p>Direct Interest</p> <ul style="list-style-type: none"><li>553,298 fully paid ordinary shares (including 400,000 American Depositary Shares (each representing 1 ordinary share) in Telix Pharmaceuticals Limited).</li><li>100,708 share options with an exercise price of \$4.38 per option and an expiry date of 26 January 2026. Options vest upon achievement of \$100M in cumulative revenue from product sales. Options allotted following shareholder approval at the AGM held 12 May 2021 (TLX0009 - TLXAL).</li><li>93,114 Performance Share Appreciation Rights (PSARs) (notional exercise price \$4.95) (TLX0012 - TLXAO) issued following shareholder approval at the AGM held 18 May 2022.</li></ul>

---

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

	<ul style="list-style-type: none"> <li>120,268 PSARs (notional exercise price \$6.90) (TLX0015 - TLXAO) issued following shareholder approval at the AGM held 24 May 2023.</li> <li>144,037 PSARs (notional exercise price \$11.94) (TLX0024 - TLXAO) issued following shareholder approval at the AGM held 22 May 2024.</li> </ul> <p>Indirect interest</p> <ul style="list-style-type: none"> <li>20,675,000 fully paid ordinary shares (Elk River Holdings Pty Ltd as Trustee for The Behrenbruch Family Trust).</li> </ul>
<b>Class</b>	<ul style="list-style-type: none"> <li>PSARs (notional exercise price \$28.67) (TLX0030 - TLXAO)</li> <li>Deferred Share Rights ex-US (nil exercise price) (TLX0031 - TLXAO)</li> </ul>
<b>Number acquired</b>	<ul style="list-style-type: none"> <li>166,483 PSARs</li> <li>2,595 Deferred Share Rights (SRs)</li> </ul>
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	<p>Non-cash consideration.</p> <ul style="list-style-type: none"> <li>PSARs were issued to Dr Behrenbruch as part of his FY25 remuneration (long term variable remuneration) following shareholder approval at the Company's AGM held 21 May 2025. The Black Scholes valuation is \$10.7997 per PSAR or \$1,797,957 in aggregate. Vesting of PSARs is subject to performance hurdles and a notional exercise price of \$28.67.</li> <li>SRs were issued to Dr Behrenbruch as part of his FY24 remuneration (short term variable remuneration) following shareholder approval at the Company's AGM held 21 May 2025. The value of each SR is \$30.39 or \$78,839 in aggregate. Vesting of SRs is subject to service condition being met and a nil exercise price.</li> </ul>

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>No. of securities held after change</b>	<p>Direct Interest</p> <ul style="list-style-type: none"> <li>553,298 fully paid ordinary shares (including 400,000 American Depositary Shares (each representing 1 ordinary share) in Telix Pharmaceuticals Limited).</li> <li>100,708 share options with an exercise price of \$4.38 per option and an expiry date of 26 January 2026. Options vest upon achievement of \$100M in cumulative revenue from product sales. Options allotted following shareholder approval at the AGM held 12 May 2021 (TLX0009 - TLXAL).</li> <li>93,114 PSARs (notional exercise price \$4.95) (TLX0012 - TLXAO) issued following shareholder approval at the AGM held 18 May 2022.</li> <li>120,268 PSARs (notional exercise price \$6.90) (TLX0015 - TLXAO) issued following shareholder approval at the AGM held 24 May 2023.</li> <li>144,037 PSARs (notional exercise price \$11.94) (TLX0024 - TLXAO) issued following shareholder approval at the AGM held 22 May 2024.</li> <li>166,483 PSARs (notional exercise price \$28.67) (TLX0030 - TLXAO) issued following shareholder approval at the AGM held 21 May 2025.</li> <li>2,595 SRs (Nil exercise price) (TLX0031 - TLXAU) issued following shareholder approval at the AGM held 21 May 2025.</li> </ul> <p>Indirect interest</p> <ul style="list-style-type: none"> <li>20,675,000 fully paid ordinary shares (Elk River Holdings Pty Ltd as Trustee for The Behrenbruch Family Trust).</li> </ul>
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Grant of PSARs and SRs under the Telix Equity Incentive Plan following shareholder approval at the Company's AGM held on 21 May 2025.

#### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

**3 – <sup>+</sup>Closed period Part**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.